1. Home
  2. > Pharmaceutical
  3. > Therapy Market Trends
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022

  • January 2022
  • 60 pages
  • ID: 6189193
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

“Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Understanding

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Overview
?-syn is an abundant 14 kDa protein consisting of 140 amino acids and comprised of three domains: an N-terminal lipid-binding alpha-helix; a non-amyloid-component (NAC); and an acidic C-terminal tail. The N-terminal domain of ?-syn is characterized by a series of seven 11-residue imperfect repeats, each based upon a highly conserved KTKEGV hexameric motif that is also observed in the ?-helical domain of apolipoproteins. Parkinson’s disease (PD) is one of the most common neurodegenerative disorders with a global burden of approximately 6.1 million patients. Alpha-synuclein has been linked to both the sporadic and familial forms of the disease. Moreover, alpha-synuclein is present in Lewy-bodies, the neuropathological hallmark of PD, and the protein and its aggregation have been widely linked to neurotoxic pathways that ultimately lead to neurodegeneration. Such pathways include autophagy/lysosomal dysregulation, synaptic dysfunction, mitochondrial disruption, and endoplasmic reticulum (ER) and oxidative stress. Alpha-synuclein has not only been shown to alter cellular pathways but also to spread between cells, causing aggregation in host cells. Therapeutic approaches will need to address several, if not all, of these angles of alpha-synuclein toxicity.

"Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline landscape is provided which includes the disease overview and Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 treatment guidelines. The assessment part of the report embraces, in depth Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 R&D. The therapies under development are focused on novel approaches to treat/improve Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021.

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Emerging Drugs Chapters
This segment of the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Emerging Drugs
• UCB0599: UCB Biopharma
UCB0599 is an investigational small molecule that prevents the pathological misfolding and accumulation of alpha-synuclein, a protein which plays a role in Parkinson’s disease (PD) pathology. Inhibition of alpha-synuclein misfolding has the potential to slow down the progression of PD. UCB0599 belongs to a series of molecules discovered by Neuropore, which was in-licensed by UCB in 2014. It is currently in Phase II stage of development.

• Prasinezumab: Prothena Corporation/Roche
Prasinezumab is a first-in-class therapeutic with the goal of reducing clinical decline in Parkinson’s disease. Prasinezumab targets ?-synuclein and is designed to block the cell-to-cell transmission of the aggregated pathogenic forms of ?-synuclein that are the cause of Parkinson’s disease, thereby slowing clinical decline. Prasinezumab is currently in Phase IIb PADOVA study and ongoing long term extension of Phase II PASADENA study. Both studies are being conducted by the partner, Roche.
Further product details are provided in the report……..

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Therapeutic Assessment
This segment of the report provides insights about the different Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021
There are approx. 13+ key companies which are developing the therapies for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021. The companies which have their Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drug candidates in the most advanced stage, i.e. Phase II include, UCB Biopharma.

• Phases
This report covers around 13+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs.

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Report Insights
• Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Pipeline Analysis

• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 Report Assessment
• Pipeline Product Profiles

• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs?
• How many Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Alpha-Synuclein (alphaSyn or SNCA) Inhibitor - Pipeline Insights, 2021 and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• UCB Biopharma
• Lundbeck A/S
• Enterin
• Ionis Pharmaceuticals
• Abbvie
• Denali Therapeutics

Key Products
• UCB0599
• Lu AF82422
• ENT-01
• ION-464
• ABBV-0805
• ATV:?Syn

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028

  • $ 3000
  • November 2022

Global Oncolytic Virus Immunotherapy Market & Clinical Trials Insight 2028 Report Overview: • Global Oncolytic Virus Immunotherapy Therapy Market Overview • Global Oncolytic Virus Immunotherapy ...

  • World
  • Therapy
  • Industry analysis
  • Mortality Rate

ref:plp2021

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on